Announcements

Editor's Choice Articles are selected based on suggestions from Cancers’ Academic Editors worldwide. The Editors select a small number of recently published articles that they consider particularly interesting to our readers or important in their respective fields of research. You are welcome to read the Editor's Choice Articles related to cancer drug development, a curated list of high-quality articles from 2022 to 2023 in Cancers (ISSN: 2072-6694).

The full list of Editor's Choice Articles can be viewed at the following link: https://www.mdpi.com/journal/cancers/editors_choice. The list of relevant papers can be seen below.

“Identification of a Novel SSTR3 Full Agonist for the Treatment of Nonfunctioning Pituitary Adenomas”
by Daniela Modena, Maria Luisa Moras, Giovanni Sandrone, Andrea Stevenazzi, Barbara Vergani, Pooja Dasgupta, Andrea Kliever, Sebastian Gulde, Alessandro Marangelo, Mathias Schillmaier et al.
Cancers 2023, 15(13), 3453; https://doi.org/10.3390/cancers15133453
Available online: https://www.mdpi.com/2072-6694/15/13/3453

“Recent Progress in Modulation of WD40-Repeat Domain 5 Protein (WDR5): Inhibitors and Degraders”
by Raju Gurung, Darlami Om, Rabin Pun, Soonsil Hyun and Dongyun Shin
Cancers 2023, 15(15), 3910; https://doi.org/10.3390/cancers15153910
Available online: https://www.mdpi.com/2072-6694/15/15/3910

“Clinical Features and Outcomes of Conversion Therapy in Patients with Unresectable Hepatocellular Carcinoma”
by Tetsu Tomonari, Joji Tani, Yasushi Sato, Hironori Tanaka, Takahiro Tanaka, Tatsuya Taniguchi, Yutaka Kawano, Asahiro Morishita, Koichi Okamoto, Masahiro Sogabe et al.
Cancers 2023, 15(21), 5221; https://doi.org/10.3390/cancers15215221
Available online: https://www.mdpi.com/2072-6694/15/21/5221

“Evaluation of Delayed-Type Hypersensitivity to Antineoplastic Drugs—An Overview”
by Inés Roger, Paula Montero, Martín Pérez-Leal, Javier Milara and Julio Cortijo
Cancers 2023, 15(4), 1208; https://doi.org/10.3390/cancers15041208
Available online: https://www.mdpi.com/2072-6694/15/4/1208

“High-Throughput Drug Screening Revealed That Ciclopirox Olamine Can Engender Gastric Cancer Stem-like Cells”
by Diana Pádua, Paula Figueira, Mariana Pinto, André Filipe Maia, Joana Peixoto, Raquel T. Lima, António Pombinho, Carlos Filipe Pereira, Raquel Almeida and Patrícia Mesquita
Cancers 2023, 15(17), 4406; https://doi.org/10.3390/cancers15174406
Available online: https://www.mdpi.com/2072-6694/15/17/4406

“Efficacy and Safety of Daratumumab, Pomalidomide, and Dexamethasone (DPd) Compared to Daratumumab, Bortezomib, and Dexamethasone (DVd) in Daratumumab–Naïve Relapsed Multiple Myeloma”
by Aimaz Afrough, Shebli Atrash, Barry Paul, Evguenia Ouchveridze, Nausheen Ahmed, Zahra Mahmoudjafari, Anam Bashir, Omar Alkharabsheh, Hamza Hashmi and Al-Ola Abdallah
Cancers 2023, 15(19), 4894; https://doi.org/10.3390/cancers15194894
Available online: https://www.mdpi.com/2072-6694/15/19/4894

“RET-Altered Cancers—A Tumor-Agnostic Review of Biology, Diagnosis and Targeted Therapy Activity”
by Antoine Desilets, Matteo Repetto, Soo-Ryum Yang, Eric J. Sherman and Alexander Drilon
Cancers 2023, 15(16), 4146; https://doi.org/10.3390/cancers15164146
Available online: https://www.mdpi.com/2072-6694/15/16/4146

“SAM-Competitive EZH2-Inhibitors Induce Platinum Resistance by EZH2-Independent Induction of ABC-Transporters”
by Elisabeth Groß, Ralf-Axel Hilger, Franziska Lea Schümann, Marcus Bauer, Alyssa Bouska, Christian Rohde, Edith Willscher, Jana Lützkendorf, Lutz Peter Müller, Bayram Edemir et al.
Cancers 2023, 15(11), 3043; https://doi.org/10.3390/cancers15113043
Available online: https://www.mdpi.com/2072-6694/15/11/3043

“Gold Nanobipyramids for Near-Infrared Fluorescence-Enhanced Imaging and Treatment of Triple-Negative Breast Cancer”
by Ioannis G. Theodorou, Fotios Mpekris, Paris Papagiorgis, Myrofora Panagi, Maria Kalli, Louiza Potamiti, Kyriacos Kyriacou, Grigorios Itskos and Triantafyllos Stylianopoulos
Cancers 2023, 15(14), 3693; https://doi.org/10.3390/cancers15143693
Available online: https://www.mdpi.com/2072-6694/15/14/3693

“A Multicenter, Open-Label, Phase I/II Study of FN-1501 in Patients with Advanced Solid Tumors”
by Gary Edward Richardson, Raed Al-Rajabi, Dipesh Uprety, Anis Hamid, Stephen K. Williamson, Joaquina Baranda, Hirva Mamdani, Ya-Li Lee, Nitika, Li Li et al.
Cancers 2023, 15(9), 2553; https://doi.org/10.3390/cancers15092553
Available online: https://www.mdpi.com/2072-6694/15/9/2553

“Computational Analysis and Experimental Testing of the Molecular Mode of Action of Gatastatin and Its Derivatives”
by Paola Vottero, Qian Wang, Marek Michalak, Maral Aminpour and Jack Adam Tuszynski
Cancers 2023, 15(6), 1714; https://doi.org/10.3390/cancers15061714
Available online: https://www.mdpi.com/2072-6694/15/6/1714

“Enhancement of Tumor Cell Immunogenicity and Antitumor Properties Derived from Platinum-Conjugated Iron Nanoparticles”
by Ángela-Patricia Hernández, Laura Iglesias-Anciones, José Javier Vaquero-González, Rafael Piñol, Julio J. Criado, Emilio Rodriguez, Pablo Juanes-Velasco, Marina L. García-Vaquero, Carlota Arias-Hidalgo, Alberto Orfao et al.
Cancers 2023, 15(12), 3204; https://doi.org/10.3390/cancers15123204
Available online: https://www.mdpi.com/2072-6694/15/12/3204

“The Role of Anesthetic Drugs and Statins in Prostate Cancer Recurrence: Starting at the Actual Knowledge and Walking through a New Paradigm”
by Aida Raigon Ponferrada, Juan Carlos Molina Ruiz, Salvador Romero Molina, Verónica Rodriguez Garcia and Jose Luis Guerrero Orriach
Cancers 2023, 15(11), 3059; https://doi.org/10.3390/cancers15113059
Available online: https://www.mdpi.com/2072-6694/15/11/3059

“Histone and DNA Methylation as Epigenetic Regulators of DNA Damage Repair in Gastric Cancer and Emerging Therapeutic Opportunities”
by Katia De Marco, Paola Sanese, Cristiano Simone and Valentina Grossi
Cancers 2023, 15(20), 4976; https://doi.org/10.3390/cancers15204976
Available online: https://www.mdpi.com/2072-6694/15/20/4976

“Genetic Profiling of Cell-Free DNA in Liquid Biopsies: A Complementary Tool for the Diagnosis of B-Cell Lymphomas and the Surveillance of Measurable Residual Disease”
by Gloria Figaredo, Alejandro Martín-Muñoz, Santiago Barrio, Laura Parrilla, Yolanda Campos-Martín, María Poza, Laura Rufián, Patrocinio Algara, Marina De La Torre, Ana Jiménez Ubieto et al.
Cancers 2023, 15(16), 4022; https://doi.org/10.3390/cancers15164022
Available online: https://www.mdpi.com/2072-6694/15/16/4022

“Metabolic Reprogramming by Ribitol Expands the Therapeutic Window of BETi JQ1 against Breast Cancer”
by Ravi Doddapaneni, Jason D. Tucker, Pei J. Lu and Qi L. Lu
Cancers 2023, 15(17), 4356; https://doi.org/10.3390/cancers15174356
Available online: https://www.mdpi.com/2072-6694/15/17/4356

“Implications of Rectal Cancer Radiotherapy on the Immune Microenvironment: Allies and Foes to Therapy Resistance and Patients’ Outcome”
by Dorothée Sartorius, Moritz Leander Blume, Johannes Robert Fleischer, Michael Ghadimi, Lena-Christin Conradi and Tiago De Oliveira
Cancers 2023, 15(21), 5124; https://doi.org/10.3390/cancers15215124
Available online: https://www.mdpi.com/2072-6694/15/21/5124

“Measurable Residual Disease (MRD) by Flow Cytometry in Adult B-Acute Lymphoblastic Leukaemia (B-ALL) and Acute Myeloid Leukaemia (AML): Correlation with Molecular MRD Testing and Clinical Outcome at One Year”
by Riana van der Linde, Prudence N. Gatt, Sandy Smith, Marian A. Fernandez, Lachlin Vaughan, Emily Blyth, Jennifer Curnow, David A. Brown, Elizabeth Tegg and Sarah C. Sasson
Cancers 2023, 15(20), 5064; https://doi.org/10.3390/cancers15205064
Available online: https://www.mdpi.com/2072-6694/15/20/5064

You are invited to view and submit relevant papers to the journal Cancers at the following link:
https://www.mdpi.com/journal/cancers.

Cancers Editorial Office